Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases

Abstract

Public-private partnerships (PPPs) for neglected tropical diseases (NTDs) are often studied as an organizational form that facilitates the management and control of the huge costs of drug research and development. Especially the later stages of drug development, including clinical trials, become very expensive. This present study investigates whether and how the type of PPPs influences the initiation and duration of NTD clinical trials. Using the ClinicalTrials.gov database, a dataset of 1175 NTD clinical studies that started between 2000 and 2021 is analyzed based on affiliation information and project duration. For the NTD clinical trials that resulted from PPPs, the collaborating types were determined and analyzed, including the public sector-, private sector-, governmental sector-, and nongovernmental organization-led collaborations. The determinants for the discontinuation of all stopped clinical trials were categorized into scientific-, funding-, political-, and logistic dimensions. The results reveal that public sector-led PPPs were the most common collaborative types, and logistic and scientific issues were the most frequent determinants of stopped clinical trials. Trial registration: ClinicalTrials.gov.

Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents

“…The phenyl/thiophene bioisosteric replacement (compounds 6 and 7/8) led to a decrease in anti-T. brucei potency. The introduction of a carboxylic group on both phenyl (9) and thiophene (10) rings resulted in a complete loss of potency (IC 50 > 40 μM), which might be related to the lack of cellular permeability due to the negatively charged carboxylate at physiological pH (c log D 7.4 : 9 = −0.51; 10 = −0.84, Table 2). The presence of an amino or hydroxyl group on the phenyl ring resulted in moderately active compounds (IC 50 11 = 25.42 μM; 12 = 14.48 μM).…”

“…falciparum) are responsible for >90% of malaria mortality worldwide, and according to the World Health Organisation (WHO), malaria cases reached 249 million in 2022 . Despite the serious health, economic, and social consequences of infections, the available treatments are associated with drawbacks including toxicity, poor efficacy, and serious side effects. , Due to the lack of funding for VBPD drug research and development, public–private partnerships have filled this gap, shifting the landscape of VBPD research and helping to decrease the disease threat on a global scale. − However, the widespread resistance of these protozoan parasites to current drugs results in an urgent need to identify new classes of antiparasitic agents. The drug discovery process targeting T.…”